View All Documents & Correspondence
Benzo[C][2,6]Naphthyridine Derivatives, Compositions And Therapeutic Uses Thereof
Abstract: Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2a) and are useful for the treatment and/or prevention of diseases and conditions in which CK2a activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2a activity is implicated.
Notices, Deadlines & Correspondence
Patent Information
Applicants
CAMBRIDGE ENTERPRISE LIMITED
Inventors
1. HYVONEN, Marko Juhana
2. BREAR, Paul
3. SPRING, David Robert
4. GLOSSOP, Paul
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202317064293-STATEMENT OF UNDERTAKING (FORM 3) [25-09-2023(online)].pdf | 2023-09-25 |
| 2 | 202317064293-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [25-09-2023(online)].pdf | 2023-09-25 |
| 3 | 202317064293-FORM 1 [25-09-2023(online)].pdf | 2023-09-25 |
| 4 | 202317064293-DECLARATION OF INVENTORSHIP (FORM 5) [25-09-2023(online)].pdf | 2023-09-25 |
| 5 | 202317064293-COMPLETE SPECIFICATION [25-09-2023(online)].pdf | 2023-09-25 |
| 6 | 202317064293-FORM-26 [12-10-2023(online)].pdf | 2023-10-12 |
| 7 | 202317064293-Proof of Right [15-12-2023(online)].pdf | 2023-12-15 |
| 8 | 202317064293-FORM 3 [05-02-2024(online)].pdf | 2024-02-05 |
| 9 | 202317064293-FORM 18 [13-12-2024(online)].pdf | 2024-12-13 |